General Information of Drug (ID: DMCEMC6)

Drug Name
GS-1811 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMCEMC6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CCX-832 DMD8QHV Psoriasis vulgaris EA90 Discontinued in Phase 1 [3]
viral macrophage inflammatory protein-II DMAXOPS Discovery agent N.A. Investigative [4]
ZK 756326 DMP089G Discovery agent N.A. Investigative [5]
I-309 DM7QE51 Discovery agent N.A. Investigative [6]
N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide DMQS9OH Discovery agent N.A. Investigative [7]
N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide DM74KHG Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 8 (CCR8) TTE836A CCR8_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT05007782) A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors. U.S.National Institutes of Health.
2 Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunology. 2022 Nov 4;11(1):2141007.
3 Increased Expression of Chemerin in Squamous Esophageal Cancer Myofibroblasts and Role in Recruitment of Mesenchymal Stromal Cells. PLoS One. 2014; 9(8): e104877.
4 HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem. 1999 Jul 30;274(31):21569-74.
5 Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol Pharmacol. 2006 Jan;69(1):309-16.
6 The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol. 1998 Jul 15;161(2):547-51.
7 Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8. J Med Chem. 2007 Feb 8;50(3):566-84.